The following is a summary of the MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript:

Financial Performance:

• MediWound reported Q1 2024 revenue of $5 million, a significant increase compared to $3.8 million in Q1 2023, primarily due to revenue from Vericel and contracts with the U.S. Department of Defense.

• The company recorded a net loss of $9.7 million or $1.05 per share in Q1 2024, a larger loss than the $3.7 million or $0.44 per share in Q1 2023.

• As of the end of Q1 2024, MediWound had a total of $36 million in cash, cash equivalents, restricted cash, and deposits.

Business Progress:

• MediWound has secured a forecast for annual revenue orders totaling $24 million, with over 60 burn centers having applied.

• Substantial progress has been recorded with NexoBrid, particularly in increasing patient numbers and orders from burn centers.

• A new state-of-the-art manufacturing facility is scheduled for completion by mid-2024, with an expectation to be fully operational by 2025.

• The FDA has accepted MediWound's supplemental BLA for NexoBrid's pediatric use, with a verdict expected later in the year.

• The company plans to conduct the Phase III clinical trial for EscharEx in the second half of 2024, targeting to enroll 216 patients across 40 sites.

• MediWound will be included in the Russell 3000 Index and the small-cap Russell 2000 Index as part of the 2024 Russell indexes reconstitution.

More details: MediWound IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.